tradingkey.logo

Beta Bionics preliminary Q4 net sales rise

ReutersJan 8, 2026 9:22 PM


Overview

  • Diabetes management firm's preliminary Q4 net sales rose, beating analyst expectations

  • DME channel net sales expected to rise 23% yr/yr in the quarter

  • PBP channel net sales expected to rise yr/yr


Outlook

  • Company did not provide specific guidance for future quarters or full year 2026


Result Drivers

  • PBP CHANNEL GROWTH - PBP channel net sales expected to rise yr/yr, driven by increased reimbursement through this channel

  • INSTALLED BASE EXPANSION - Installed customer base expected to grow yr/yr, reflecting strong adoption of iLet Bionic Pancreas

  • NEW PATIENT STARTS - New patient starts expected to increase 36% yr/yr, with 69% coming from multiple daily injections


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Net sales

Beat

$32 mln

$28.90 mln (10 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Beta Bionics Inc is $32.50, about 3.2% above its January 7 closing price of $31.49

Press Release: ID:nGNX9Dyf1M

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI